Clinical studies

Limicol, a food supplement with efficacy proven
in 3 clinical trials

Total cholesterol reduction as of month 1

Graph 1 LIMICOL

During the 1st clinical trial, daily intake of 3 tablets of Limicol enabled a significant mean reduction in total cholesterol of 15.3% as of the 1st month and stabilization of total cholesterol levels over the following 3 months.

No significant decrease was observed in the placebo group. The results were confirmed by the 2nd and 3rd trials (13.0 and 12.0% reduction in total cholesterol, respectively).

Mean results obtained after 1 month of supplementation for the Limicol group (3 tablets/day).
Clinical trial No. 1 conducted on 39 subjects supplemented with Limicol or placebo for 4 months.

LDL cholesterol reducation as of month 1

During the 1st clinical trial, daily intake of 3 tablets of Limicol enabled a significant mean reduction in LDL cholesterol of 21.4% as of the 1st month and stabilisation of LDL cholesterol over the following 3 months (19.7% reduction after 4 months of supplementation).

No significant reduction was observed in the placebo group. The results were confirmed by the 2nd and 3rd trials (19.8 and 20.4% reduction in LDL cholesterol, respectively).

Graph 2 Limicol

Mean results obtained after 1 month of supplementation for the Limicol group (3 tablets/day).
Clinical trial No. 1 conducted on 39 subjects supplemented with Limicol or placebo for 4 months.

No discomfort observed

During the studies, none of the volunteers reported any moderate or serious adverse events, thus demonstrating the excellent safety profile of Limicol.